Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

NeoStem Acquires Asia Rights to Stem Cell Treatment

publication date: May 11, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NeoStem, Inc. in-licensed the Asia rights for Regenrexx™, a process that uses a patient’s own mesenchymal stem cells to regenerate joints and bones as an alternative to surgery. Regenerexx was the second mesenchymal stem cell in-licensing deal for NeoStem in as many weeks. Last week, NeoStem announced it had acquired worldwide rights for Primcel, a product that aids wound healing. More details...

Stock Symbol: (NYSE Amex: NBS)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...